Literature DB >> 28112749

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for younger patients with acute myeloid leukemia: a registry-based study.

M Yanada1, S Kurosawa2, T Kobayashi3, Y Ozawa4, H Kanamori5, N Kobayashi6, M Sawa7, H Nakamae8, N Uchida9, H Hashimoto10, T Fukuda2, M Hirokawa11, Y Atsuta12,13, S Yano14.   

Abstract

Clinical efficacy of allogeneic hematopoietic cell transplantation (HCT) using reduced-intensity conditioning (RIC) for younger patients remains unclear. We therefore performed a retrospective registry-based study to evaluate outcomes for patients with AML aged between 16 and 49 years who underwent RIC allogeneic HCT. Patients receiving RIC (N=125) showed significantly worse survival than those receiving myeloablative conditioning (MAC; N=1,554) (47.7% for RIC and 54.2% for MAC at 4 years, P=0.047). However, the difference became marginal after adjustment for patient characteristics (P=0.080), and inclusion in the multivariate analysis of the HCT comorbidity index or the propensity score for estimating the likelihood of choosing RIC or MAC further reduced statistical significance (P=0.371 and 0.206, respectively), indicating the existence of a selection bias against RIC. Nevertheless, outcomes for our patients receiving RIC were still acceptable, so that RIC constitutes a potential therapeutic option for younger AML patients who are deemed unsuitable for MAC. Subgroup analyses showed that patients aged between 40 and 49 years as well as those in first or second CR at the time of transplantation exhibited similar outcomes regardless of whether they were treated with RIC or MAC.

Entities:  

Mesh:

Year:  2017        PMID: 28112749     DOI: 10.1038/bmt.2016.358

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  25 in total

1.  Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

Authors:  Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka
Journal:  Cancer       Date:  2006-06-01       Impact factor: 6.860

2.  Estimating treatment effects using observational data.

Authors:  Ralph B D'Agostino; Ralph B D'Agostino
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 3.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

Authors:  K M Sullivan; E Agura; C Anasetti; F Appelbaum; C Badger; S Bearman; K Erickson; M Flowers; J Hansen; T Loughran
Journal:  Semin Hematol       Date:  1991-07       Impact factor: 3.851

4.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

5.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

6.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Authors:  C Cutler; S Giri; S Jeyapalan; D Paniagua; A Viswanathan; J H Antin
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

7.  Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System.

Authors:  Yoshiko Atsuta; Ritsuro Suzuki; Ayami Yoshimi; Hisashi Gondo; Junji Tanaka; Akira Hiraoka; Koji Kato; Ken Tabuchi; Masahiro Tsuchida; Yasuo Morishima; Makoto Mitamura; Keisei Kawa; Shunichi Kato; Tokiko Nagamura; Minoko Takanashi; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2007-10       Impact factor: 2.490

8.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

9.  Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT.

Authors:  R Martino; L de Wreede; M Fiocco; A van Biezen; P A von dem Borne; R-M Hamladji; L Volin; M Bornhäuser; M Robin; V Rocha; T de Witte; N Kröger; M Mohty
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

Review 10.  Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.

Authors:  Masamitsu Yanada
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

View more
  2 in total

Review 1.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

2.  Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia.

Authors:  Masamitsu Yanada; Takaaki Konuma; Shohei Mizuno; Masuho Saburi; Akihito Shinohara; Masatsugu Tanaka; Atsushi Marumo; Masashi Sawa; Naoyuki Uchida; Yukiyasu Ozawa; Makoto Onizuka; Satoshi Yoshioka; Hirohisa Nakamae; Tadakazu Kondo; Takafumi Kimura; Junya Kanda; Takahiro Fukuda; Yoshiko Atsuta; Hideki Nakasone; Shingo Yano
Journal:  Bone Marrow Transplant       Date:  2020-08-14       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.